NASDAQ$TECX
Tectonic Therapeutic Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
AVROBIO reported financial results for the quarter ended Sept. 30, 2021, and provided a business update.
AVROBIO reported a net loss of $32.6 million for the third quarter of 2021, driven by decreased research and development expenses, partially offset by increased general and administrative expenses. They ended the quarter with $201.4 million in cash and cash equivalents.
- Provided comprehensive safety update on AVROBIO’s lentiviral gene therapy platform and programs at ESGCT 2021
- Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial; registration study initiation anticipated for mid-2022
- Cash runway extended into fourth quarter of 2023
- Secured up to $65 million in availability of non-dilutive term loan financing
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Forward guidance
AVROBIO anticipates multiple program milestones over the next 12 months, including efficacy data updates for Fabry disease trials, clinical and regulatory updates for cystinosis, and full program updates for Gaucher disease type 1. They also plan to engage regulatory agencies for Gaucher disease type 3 and initiate clinical trials for Pompe and Hunter syndromes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2021
-1.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro